Prosecution Insights
Last updated: October 23, 2026
Application No. 18/722,521

ANTIMICROBIAL SYSTEM WITH BETA CARBOLINE ALKALOID AND PHENOLIC ACID AND COMPOSITIONS COMPRISING THEM

Non-Final OA §112
Filed
Jun 20, 2024
Priority
Dec 27, 2021 — EU 21217788.5 +1 more
Examiner
KIFLE, BRUCK
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Conopco, Inc. d/b/a Unilever
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
1381 granted / 1742 resolved
+19.3% vs TC avg
Strong +16% interview lift
Without
With
+15.8%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 10m
Avg Prosecution
46 currently pending
Career history
1788
Total Applications
across all art units

Statute-Specific Performance

§101
5.9%
-34.1% vs TC avg
§103
12.7%
-27.3% vs TC avg
§102
12.2%
-27.8% vs TC avg
§112
53.9%
+13.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1742 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-9 are presented for examination. Claims 1 and 4 are the independent claims. Claim Rejections - 35 USC § 112 Claims 1-9 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claims 1 and 4 recite the broad recitation of the structural formula of the beta carboline alkaloid and phenolic acid, and the claim also recites the compounds 1-methyl-9H-pyrido[3,4-b]indol-7-ol and 4-hydroxy-3,5-dimethoxybenzoic acid which are the narrower species of the genus of the limitation. The claims are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter: Subject matter directed to compositions comprising 1-methyl-9H-pyrido[3,4-b]indol-7-ol and 4-hydroxy-3,5-dimethoxybenzoic acid or a salt thereof would be allowable. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRUCK KIFLE whose telephone number is (571)272-0668. The examiner can normally be reached 8 AM - 6 PM, M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey H. Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. September 24, 2026 /BRUCK KIFLE/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Jun 20, 2024
Application Filed
Sep 28, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766146
Salts and Solid Form of a BTK Inhibitor
4y 5m to grant Granted Oct 20, 2026
Patent 12767637
MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES
3y 11m to grant Granted Oct 20, 2026
Patent 12765555
METHOD FOR CONTROLLING WEEDS
3y 3m to grant Granted Oct 20, 2026
Patent 12766152
GEL COMPOSITION FOR PREVENTION OR TREATMENT OF ATOPIC DERMATITIS
2y 7m to grant Granted Oct 20, 2026
Patent 12760005
BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS
3y 8m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
95%
With Interview (+15.8%)
1y 10m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1742 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month